Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$916K Sell
3,639
-1,032
-22% -$222K 0.37% 53
2026
Q1
$1.02M Sell
4,671
-53
-1% -$11.8K 0.45% 43
2025
Q4
$1.08M Buy
+4,724
New +$1.08M 0.47% 41
2025
Q2
$893K Sell
4,724
-226
-5% -$42K 0.41% 47
2025
Q1
$1.04M Sell
4,950
-94
-2% -$18.3K 0.51% 38
2024
Q4
$896K Sell
5,044
-75
-1% -$13.8K 0.44% 48
2024
Q3
$1.01M Buy
5,119
+5
+0.1% +$933 0.5% 45
2024
Q2
$877K Sell
5,114
-583
-10% -$96.6K 0.46% 50
2024
Q1
$1.04M Sell
5,697
-130
-2% -$22.4K 0.54% 41
2023
Q4
$903K Buy
5,827
+215
+4% +$31.3K 0.51% 49
2023
Q3
$837K Buy
5,612
+323
+6% +$47.4K 0.52% 50
2023
Q2
$791K Buy
+5,289
New +$776K 0.47% 56

Other funds holding ABBV

Union Savings Bank's ABBV Position: Q2 2026 in Review

Union Savings Bank reduced its AbbVie (ABBV) stake by 22% in Q2 2026, selling an estimated $222K and leaving 3,639 shares worth $916K. The position accounts for 0.37% of the portfolio, ranked #53.

Union Savings Bank first reported a position in ABBV in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.08M in Q4 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Union Savings Bank held 3,639 shares of AbbVie worth $916K as of Q2 2026.
  • Union Savings Bank sold 1,032 AbbVie shares in Q2 2026, an estimated $222K.
  • AbbVie made up 0.37% of Union Savings Bank's portfolio in Q2 2026, its #53 holding.
  • Union Savings Bank first reported a position in AbbVie in Q2 2023 and has held it in 12 quarters since.
  • Union Savings Bank's AbbVie position peaked at $1.08M in Q4 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Union Savings Bank's 13F filing for Q2 2026, filed 23 Jul 2026.